Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Edward J FoxClyde MarkowitzAngela ApplebeeXavier MontalbanJerry S WolinskyShibeshih BelachewDamian FioreJinglan PeiBruno MuschGavin GiovannoniPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
Ocrelizumab reduces the risk of UE disability progression and may increase the possibility of improvement versus placebo in PPMS.